KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $19.37 $28.23 Friday, 26th Apr 2024 NTLA stock ended at $20.76. This is 3.70% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 8.34% from a day low at $19.37 to a day high of $20.99.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Apr 26, 2024 $20.11 $20.99 $19.37 $20.76 994 220
Apr 25, 2024 $20.53 $20.66 $19.64 $20.02 1 411 532
Apr 24, 2024 $21.56 $21.73 $21.03 $21.17 838 511
Apr 23, 2024 $21.78 $22.85 $21.52 $21.53 848 177
Apr 22, 2024 $21.75 $22.20 $20.88 $21.83 987 218
Apr 19, 2024 $21.22 $21.63 $20.78 $21.57 1 280 443
Apr 18, 2024 $21.37 $21.85 $21.18 $21.32 1 114 495
Apr 17, 2024 $21.94 $22.13 $21.45 $21.50 1 027 959
Apr 16, 2024 $22.62 $22.84 $21.80 $21.81 1 187 859
Apr 15, 2024 $24.13 $24.15 $22.51 $22.92 1 522 322
Apr 12, 2024 $24.83 $24.99 $23.96 $24.27 1 242 793
Apr 11, 2024 $25.29 $25.53 $24.42 $25.01 1 347 477
Apr 10, 2024 $24.76 $25.19 $24.38 $24.95 1 495 391
Apr 09, 2024 $25.46 $26.23 $25.33 $26.08 878 718
Apr 08, 2024 $24.75 $25.49 $24.75 $25.30 892 728
Apr 05, 2024 $24.54 $25.26 $24.34 $24.78 850 233
Apr 04, 2024 $25.32 $25.56 $24.75 $24.97 1 208 882
Apr 03, 2024 $25.00 $25.54 $24.34 $24.98 1 163 252
Apr 02, 2024 $26.38 $26.38 $25.07 $25.10 1 894 161
Apr 01, 2024 $27.43 $27.46 $26.60 $27.22 825 016
Mar 28, 2024 $26.98 $28.23 $26.61 $27.51 1 042 955
Mar 27, 2024 $26.50 $27.46 $26.08 $27.02 1 137 446
Mar 26, 2024 $27.19 $27.55 $26.21 $26.26 938 316
Mar 25, 2024 $26.95 $27.29 $26.74 $26.83 700 561
Mar 22, 2024 $27.62 $27.62 $26.83 $26.91 768 565
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT